Clinical, Cytogenetic and Molecular Characterization of a 96 MDS and AML Cohort with TP53 Mutation

被引：0

作者：

Duranjou, Marine ^{[1
]}

Castoldi, Cecile ^{[2
]}

Alary, Anne Sophie

Hicheri, Yosr ^{[2
]}

Saillard, Colombe ^{[2
]}

Rouzaud, Camille

Charbonnier, Aude ^{[2
]}

Mohty, Bilal ^{[2
]}

D'Incan, Evelyne ^{[2
]}

Rey, Jerome ^{[2
]}

Devillier, Raynier ^{[3
]}

Vey, Norbert ^{[4
]}

Gelsi-Boyer, Veronique ^{[1
]}

Lhoumeau, Anne-Catherine ^{[1
]}

Murati, Anne ^{[1
]}

Golesi, Florence ^{[1
]}

Mozziconacci, Marie Joelle ^{[1
]}

Ittel, Antoine ^{[1
]}

Garciaz, Sylvain ^{[5
]}

机构：

[1] Inst Paoli Calmettes, Dept Biopathol, Marseille, France

[2] Inst Paoli Calmettes, Dept Hematol, Marseille, France

[3] Aix Marseille Univ, Inst Paoli Calmettes, Hematol & Transplantat, Marseille, France

[4] Aix Marseille Univ, Inst Paoli Calmettes, INSERM,U1068, CNRS,CRCM, Marseille, France

[5] Aix Marseille Univ, Hematol Dept, Integrat Struct & Chem Biol, Inserm,CNRS,Inst Paoli Calmettes,Ctr Rech Cancero, Marseille, France

来源：

BLOOD | 2023年 / 142卷

关键词：

D O I：

10.1182/blood-2023-186086

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页数：4

共 50 条

[21] TP53 Splice-Site Mutations in Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML): A Clinicopathologic and Cytogenetic Correlation
Narvaez, Sofia Garces
Modi, Mitul
Morrissette, Jennifer
Rosenbaum, Jason
Priore, Salvatore
MODERN PATHOLOGY, 2020, 33 (SUPPL 2) : 1299 - 1299
[22] TP53 Splice-Site Mutations in Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML): A Clinicopathologic and Cytogenetic Correlation
Narvaez, Sofia Garces
Modi, Mitul
Morrissette, Jennifer
Rosenbaum, Jason
Priore, Salvatore
LABORATORY INVESTIGATION, 2020, 100 (SUPPL 1) : 1299 - 1299
[23] Reply to Goel et al. ‘TP53 mutation allele-burden and disease outcome in MDS/AML’
D A Sallman
R Komrokji
A List
E Padron
Leukemia, 2017, 31 : 767 - 768
[24] Reply to Goel et al. 'TP53 mutation allele- burden and disease outcome in MDS/AML'
Sallman, D. A.
Komrokji, R.
List, A.
Padron, E.
LEUKEMIA, 2017, 31 (03) : 767 - 768
[25] Molecular mechanism in prostate cancer with TP53 mutation
Hu, B.
Liu, H.
Zhang, Y.
Wang, H.
ANNALS OF ONCOLOGY, 2022, 33 : S1606 - S1606
[26] TP53 as a biomarker of cytogenetic damage
Hendrikse, A
Hunter, A
Blekkenhorst, G
HEALTH PHYSICS, 2000, 78 (06): : 753 - 753
[27] Isolated TP53 Mutations Portend Worse Prognosis in MDS and AML Compared to TP53 Mutations with Concurrent Myeloid-Associated Mutations
Hussaini, Mohammad
Abuel-Haija, Mohammad
Padron, Eric
David, Sallman
Song, Jinming
MODERN PATHOLOGY, 2018, 31 : 524 - 525
[28] Isolated TP53 Mutations Portend Worse Prognosis in MDS and AML Compared to TP53 Mutations with Concurrent Myeloid-Associated Mutations
Hussaini, Mohammad
Abuel-Haija, Mohammad
Padron, Eric
David, Sallman
Song, Jinming
LABORATORY INVESTIGATION, 2018, 98 : 524 - 525
[29] Distinct Implications of TP53 Hits for Patients with Treatment-Related MDS and AML
Kuzmanovic, Teodora
Patel, Bhumika J.
Nagata, Yasunobu
Awada, Hassan
Hirsch, Cassandra M.
Przychodzen, Bartlomiej P.
Sanikommu, Srinivasa Reddy
Williams, Louis
Mukherjee, Sudipto
Advani, Anjali S.
Nazha, Aziz
Gerds, Aaron T.
Radivoyevitch, Tomas
Carraway, Hetty E.
Sekeres, Mikkael A.
Maciejewski, Jaroslaw P.
BLOOD, 2018, 132
[30] Mutation and function of TP53
Milner, J
BRAIN PATHOLOGY, 2000, 10 (04) : 504 - 504

← 1 2 3 4 5 →